Dynavax Technologies · 2 weeks ago
IDN Key Account Executive II - Los Angeles South, CA
Dynavax Technologies is a commercial-stage biopharmaceutical company focused on developing and commercializing novel vaccines for infectious diseases. The IDN Key Account Executive II will manage assigned accounts to drive sales of HEPLISAV-B, requiring deep understanding of vaccine decision-making and the ability to develop strategic relationships with key stakeholders.
BiopharmaBiotechnologyClinical TrialsHealth CareMedical Device
Responsibilities
Responsible for achieving sales targets and owning/managing customer relationships for assigned Accounts. Assigned accounts will include large IDNs, independent customers and group practices
Serves as sole owner for assigned accounts – responsible for successful execution at all levels of the customer organization to achieve declared goals/objectives
Demonstrates a deep understanding of vaccine decision making, vaccine adoption and implementation process and key decision makers across all levels of assigned accounts
Responsible for developing, communicating, and monitoring an account strategy for each assigned account. Conducts quarterly business reviews with Director, Vaccine Sales
Execute all functions of the role independently with minimal supervision from the Director, Vaccine Sales and/or assigned mentor for executive level customer engagements
Develop relationships with key stakeholders at each level of organization who are responsible for implementation of vaccines
Partner with Director, Vaccine Sales to execute sales & marketing strategies to support HEPLISAV-B expansion within assigned accounts
Responsible for understanding competitive positioning, market dynamics and customer business models to identify opportunities across assigned accounts
Maintain accurate up-to-date customer records in the Account Management system
Exercise sound judgement and oversight to ensure integrity and compliance with company policies in all activities and communications
Foster Dynavax core values and leadership behaviors
Other duties as assigned
Qualification
Required
Bachelor's Degree required from an accredited institution
3+ years of life sciences sales experience required
2 years of vaccine or buy & bill experience required
Knowledge of the IDN/Hospital landscape within assigned territory required
Strong proven strategic vision, business acumen and influencing skills to drive strategic and operational initiatives across the organization
Documented track record of consistent sales and growth success along with superb account management skills
Proven track record of financial/budget management experience
Knowledge of large health systems, including immunization related quality initiatives
Excellent oral and written communication skills, presentation and influencing skills
Ability to drive business results and identify new opportunities and strategies through strategic thinking and business planning
Experience in matrix management, change advocate
Heavy travel required
Key Competencies: Accountability, Customer Engagement, Customer Discovery, Business Acumen, Executional Effectiveness
Ability to operate a motor vehicle
Ability to sit for prolonged periods; reach with arms and hands; lift and move small objects; and use hands to keyboard and perform other office related tasks including repetitive movement of the wrists, hands and/or fingers
Must be able to obtain all industry credentials and certifications
Preferred
MBA preferred
IDN/Hospital experience preferred
2+ years of strategic account management experience preferred
Previous health system account management experience is highly preferred
C-suite leadership and account management experience within IDNs and Hospitals is highly preferred
Benefits
Stock equity awards
Participation in our Company’s sales incentive compensation program
Company car
Full range of health and welfare insurance benefits
401(k) company match
Paid time off benefits
17 paid holidays in 2025
Company
Dynavax Technologies
Dynavax Technologies is a biopharmaceutical company discovering and developing novel products to prevent and treat infectious diseases.
Funding
Current Stage
Public CompanyTotal Funding
$1.58BKey Investors
Bill & Melinda Gates FoundationHercules CapitalNational Institute of Allergy and Infectious Diseases
2025-12-24Acquired
2025-03-06Post Ipo Debt· $225M
2021-05-11Post Ipo Debt· $200M
Recent News
2026-01-08
Company data provided by crunchbase